SCHEMBL3016635

SCHEMBL3016635

COc1ccc(Cl)cc1S(=O)(=O)N1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
MAPK1 P28482 1/20 0.59
ALDH1A1 P00352 6/20 0.55
HPGD P15428 2/20 0.55
KDM4E B2RXH2 2/20 0.55
POLB P06746 1/20 0.55
RAB9A P51151 1/20 0.55
MAPT P10636 7/20 0.54
TSHR P16473 1/20 0.54
RECQL P46063 3/20 0.53
HSD17B10 Q99714 2/20 0.53
USP2 O75604 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 1/20 0.51
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011380 0.94 ALDH1A1 (0.57) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL17510126 0.93 LMNA (0.52) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3010848 0.91 ALDH1A1 (0.54) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3009587 0.91 POLB (0.56) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3007942 0.91 ALDH1A1 (0.56) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3015434 0.91 MAPT (0.66) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3018215 0.91 MAPT (0.54) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3016726 0.90 MAPT (0.59) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3007037 0.90 MAPT (0.54) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL3001254 0.90 ALDH1A1 (0.54) LMNAMEN1KMT2AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.